 The novel coronavirus disease, COVID-19, has had a serious impact on people's lives for more than three years now. The severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, has caused significant damage to people's respiratory systems and multiple organs. Despite the full understanding of the pathogenesis of COVID-19, there is still a lack of effective and specific treatment for it. Mesenchymal stem cells, MSCs, or MSC-derived extracellular vesicles, MSC versus, are being considered as one of the most promising candidates for treating severe COVID-19. These cells have demonstrated their potential to treat the virus, and they have already been used in clinical trials. MSCs have shown their ability to modulate various immune cells and organs, which makes them ideal candidates for treating COVID-19. They can help reduce the severity of symptoms, improve patient outcomes, and even potentially cure the virus. Additionally, MSCs have the potential to regenerate damaged tissues and organs, making them a valuable tool in combating. This article was authored by Yuyin Feng, Peijun Lao, Longxian Tang, and others. We are article.tv, links in the description below.